Literature DB >> 10823245

Immunoglobulin light chains, glycosaminoglycans, and amyloid.

F J Stevens1, R Kisilevsky.   

Abstract

Immunoglobulin light chains are the precursor proteins for fibrils that are formed during primary amyloidosis and in amyloidosis associated with multiple myeloma. As found for the approximately 20 currently described forms of focal, localized, or systemic amyloidoses, light chain-related fibrils extracted from physiological deposits are invariably associated with glycosaminoglycans, predominantly heparan sulfate. Other amyloid-related proteins are either structurally normal, such as beta2-microglobulin and islet amyloid polypeptide, fragments of normal proteins such as serum amyloid A protein or the precursor protein of the beta peptide involved in Alzheimer's disease, or are inherited forms of single amino acid variants of a normal protein such as found in the familial forms of amyloid associated with transthyretin. In contrast, the primary structures of light chains involved in fibril formation exhibit extensive mutational diversity rendering some proteins highly amyloidogenic and others non-pathological. The interactions between light chains and glycosaminoglycans are also affected by amino acid variation and may influence the clinical course of disease by enhancing fibril stability and contributing to resistance to protease degradation. Relatively little is currently known about the mechanisms by which glycosaminoglycans interact with light chains and light-chain fibrils. It is probable that future studies of this uniquely diverse family of proteins will continue to shed light on the processes of amyloidosis, and contribute as well to a greater understanding of the normal physiological roles of glycosaminoglycans.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10823245     DOI: 10.1007/PL00000706

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  12 in total

1.  Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils.

Authors:  Ruiyi Ren; Zhenning Hong; Haiyan Gong; Kate Laporte; Martha Skinner; David C Seldin; Catherine E Costello; Lawreen H Connors; Vickery Trinkaus-Randall
Journal:  J Biol Chem       Date:  2010-09-24       Impact factor: 5.157

2.  The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis.

Authors:  X Jiang; J N Buxbaum; J W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

3.  Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans.

Authors:  Luis M Blancas-Mejía; Jared Hammernik; Marta Marin-Argany; Marina Ramirez-Alvarado
Journal:  J Biol Chem       Date:  2014-12-23       Impact factor: 5.157

4.  Detection of high-molecular-weight amyloid serum protein complexes using biological on-line tracer sedimentation.

Authors:  Jonathan S Kingsbury; Thomas M Laue; Susan F Chase; Lawreen H Connors
Journal:  Anal Biochem       Date:  2012-03-27       Impact factor: 3.365

5.  Transgenic over-expression of mammalian heparanase delays prion disease onset and progression.

Authors:  O Kovalchuk Ben-Zaken; I Nissan; S Tzaban; A Taraboulos; E Zcharia; S Matzger; I Shafat; I Vlodavsky; Y Tal
Journal:  Biochem Biophys Res Commun       Date:  2015-07-10       Impact factor: 3.575

6.  Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.

Authors:  Bonnie K Arendt; Marina Ramirez-Alvarado; Laura A Sikkink; Jonathan J Keats; Gregory J Ahmann; Angela Dispenzieri; Rafael Fonseca; Rhett P Ketterling; Ryan A Knudson; Erin M Mulvihill; Renee C Tschumper; Xiaosheng Wu; Steven R Zeldenrust; Diane F Jelinek
Journal:  Blood       Date:  2008-06-20       Impact factor: 22.113

7.  Peptide p5 binds both heparinase-sensitive glycosaminoglycans and fibrils in patient-derived AL amyloid extracts.

Authors:  Emily B Martin; Angela Williams; Eric Heidel; Sallie Macy; Stephen J Kennel; Jonathan S Wall
Journal:  Biochem Biophys Res Commun       Date:  2013-05-23       Impact factor: 3.575

8.  Cellular response of cardiac fibroblasts to amyloidogenic light chains.

Authors:  Vickery Trinkaus-Randall; Mary T Walsh; Shawn Steeves; Grace Monis; Lawreen H Connors; Martha Skinner
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

Review 9.  Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis.

Authors:  Jan M Griffin; Hannah Rosenblum; Mathew S Maurer
Journal:  Circ Res       Date:  2021-05-13       Impact factor: 17.367

10.  In vitro aggregation behavior of a non-amyloidogenic λ light chain dimer deriving from U266 multiple myeloma cells.

Authors:  Paolo Arosio; Marta Owczarz; Thomas Müller-Späth; Paola Rognoni; Marten Beeg; Hua Wu; Mario Salmona; Massimo Morbidelli
Journal:  PLoS One       Date:  2012-03-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.